INTRODUCTION: A limitation of drug-eluting stent (DES) use to FDA-approved indications has been suggested to reduce the risk of stent thrombosis. This study evaluated predictors of stent thrombosis in clinical practice after the use of drug-eluting as well as bare-metal stents (BMS), including adherence to the FDA indications for DES. METHODS: Between July 2002 and October 2006 percutaneous coronary intervention (PCI) was performed on 5,945 patients using BMS (68%) or DES (32%). Patients had 1-year follow-up for definitive stent thrombosis (ARC criteria). 76 patients (1.27%) developed definitive stent thrombosis. Clinical, procedural, and angiographic parameters were related to those of 786 patients without stent thrombosis to define predictors of stent thrombosis. Off-label or on-label implantation of stents according to the FDA-approved indications for DES was included as parameter in the analysis. RESULTS: In 434 patients, stent implantation was performed within FDA-approved indications and in 428 patients outside of FDA-approved indications for DES. Predictors of stent thrombosis were PCI in acute myocardial infarction (OR = 4.51, P < 0.001), treatment of bifurcation lesions (OR = 4.43, P < 0.001), stent length per mm (OR = 1.07, P < 0.001), implantation of multiple stents (OR = 3.67, P < 0.001), and stent implantation outside of FDA indications (OR = 6.13, P < 0.001). The risk was increased for DES as well as BMS. In a multivariate analysis, PCI in acute myocardial infarction (OR = 2.56, P = 0.014), LV-EF < 30% (OR = 3.60, P < 0.001), treatment of bifurcation lesion (OR = 3.65, P = 0.004), stent length in mm (OR = 1.04, P = 0.015), and implantation of multiple stents (OR = 2.64, P = 0.002) remained predictors of stent thrombosis. Off-label stent implantation was no independent additional predictor as it is a combined parameter of the above-mentioned predictors. CONCLUSIONS: Implantation of coronary stents outside of the FDA-approved indications for DES is associated with an increased risk of stent thrombosis using DES and BMS.
INTRODUCTION: A limitation of drug-eluting stent (DES) use to FDA-approved indications has been suggested to reduce the risk of stent thrombosis. This study evaluated predictors of stent thrombosis in clinical practice after the use of drug-eluting as well as bare-metal stents (BMS), including adherence to the FDA indications for DES. METHODS: Between July 2002 and October 2006 percutaneous coronary intervention (PCI) was performed on 5,945 patients using BMS (68%) or DES (32%). Patients had 1-year follow-up for definitive stent thrombosis (ARC criteria). 76 patients (1.27%) developed definitive stent thrombosis. Clinical, procedural, and angiographic parameters were related to those of 786 patients without stent thrombosis to define predictors of stent thrombosis. Off-label or on-label implantation of stents according to the FDA-approved indications for DES was included as parameter in the analysis. RESULTS: In 434 patients, stent implantation was performed within FDA-approved indications and in 428 patients outside of FDA-approved indications for DES. Predictors of stent thrombosis were PCI in acute myocardial infarction (OR = 4.51, P < 0.001), treatment of bifurcation lesions (OR = 4.43, P < 0.001), stent length per mm (OR = 1.07, P < 0.001), implantation of multiple stents (OR = 3.67, P < 0.001), and stent implantation outside of FDA indications (OR = 6.13, P < 0.001). The risk was increased for DES as well as BMS. In a multivariate analysis, PCI in acute myocardial infarction (OR = 2.56, P = 0.014), LV-EF < 30% (OR = 3.60, P < 0.001), treatment of bifurcation lesion (OR = 3.65, P = 0.004), stent length in mm (OR = 1.04, P = 0.015), and implantation of multiple stents (OR = 2.64, P = 0.002) remained predictors of stent thrombosis. Off-label stent implantation was no independent additional predictor as it is a combined parameter of the above-mentioned predictors. CONCLUSIONS: Implantation of coronary stents outside of the FDA-approved indications for DES is associated with an increased risk of stent thrombosis using DES and BMS.
Authors: Michael Joner; Aloke V Finn; Andrew Farb; Erik K Mont; Frank D Kolodgie; Elena Ladich; Robert Kutys; Kristi Skorija; Herman K Gold; Renu Virmani Journal: J Am Coll Cardiol Date: 2006-05-05 Impact factor: 24.094
Authors: Anthony A Bavry; Dharam J Kumbhani; Thomas J Helton; Przemyslaw P Borek; Girish R Mood; Deepak L Bhatt Journal: Am J Med Date: 2006-12 Impact factor: 4.965
Authors: Htut K Win; Angel E Caldera; Kelly Maresh; John Lopez; Charanjit S Rihal; Manish A Parikh; Juan F Granada; Sachin Marulkar; Deborah Nassif; David J Cohen; Neal S Kleiman Journal: JAMA Date: 2007-05-09 Impact factor: 56.272
Authors: Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell Journal: N Engl J Med Date: 2004-01-15 Impact factor: 91.245
Authors: D L Fischman; M B Leon; D S Baim; R A Schatz; M P Savage; I Penn; K Detre; L Veltri; D Ricci; M Nobuyoshi Journal: N Engl J Med Date: 1994-08-25 Impact factor: 91.245
Authors: Ibrahim Akin; Marcus Wiemer; Steffen Schneider; Jochen Senges; Matthias Hochadel; Gert Richardt; Mohamed Abdel-Wahab; Karl-Heinz Kuck; Christoph A Nienaber Journal: Clin Res Cardiol Date: 2011-11-13 Impact factor: 5.460
Authors: Artur Dziewierz; Zbigniew Siudak; Tomasz Rakowski; Ralf Birkemeyer; Waldemar Mielecki; Paweł Ranosz; Jacek S Dubiel; Dariusz Dudek Journal: Clin Res Cardiol Date: 2010-09-18 Impact factor: 5.460
Authors: Giuseppe Biondi-Zoccai; Imad Sheiban; Enrico Romagnoli; Stefano De Servi; Corrado Tamburino; Antonio Colombo; Francesco Burzotta; Patrizia Presbitero; Leonardo Bolognese; Leonardo Paloscia; Paolo Rubino; Gennaro Sardella; Carlo Briguori; Luigi Niccoli; Gianfranco Franco; Domenico Di Girolamo; Luigi Piatti; Cesare Greco; Davide Capodanno; Giuseppe Sangiorgi Journal: Clin Res Cardiol Date: 2011-06-24 Impact factor: 5.460
Authors: Timm Bauer; Christoph A Nienaber; Ibrahim Akin; Karl-Heinz Kuck; Matthias Hochadel; Jochen Senges; Thomas Fetsch; Ulrich Tebbe; Stefan N Willich; Jürgen Stumpf; Georg V Sabin; Sigmund Silber; Gert Richardt; Ralf Zahn Journal: Clin Res Cardiol Date: 2011-03-18 Impact factor: 5.460
Authors: Ibrahim Akin; Alexander Bufe; Steffen Schneider; Holger Reinecke; Lars Eckardt; Gert Richardt; Detlev Burska; Jochen Senges; Karl-Heinz Kuck; Christoph A Nienaber Journal: Clin Res Cardiol Date: 2010-03-11 Impact factor: 5.460
Authors: Alban Dibra; Klaus Tiroch; Stefanie Schulz; Henning Kelbaek; Christian Spaulding; Gerrit J Laarman; Marco Valgimigli; Emilio Di Lorenzo; Christoph Kaiser; Ilkka Tierala; Julinda Mehilli; Gianluca Campo; Leif Thuesen; Maarten A Vink; Martin J Schalij; Roberto Violini; Albert Schömig; Adnan Kastrati Journal: Clin Res Cardiol Date: 2010-03-11 Impact factor: 5.460